GNI Group completes JPY 44.8bn acquisition of Ayumi Pharmaceutical
GNI Group has completed its acquisition of Ayumi Pharmaceutical Holdings and its operating subsidiary Ayumi Pharmaceutical, formerly held by funds managed by Blackstone. The transaction, settled through a combination of cash and newly issued GNI shares, was struck at an enterprise value of approximately JPY 44.8 billion (roughly £240 million at current rates). Blackstone, along with Japanese distributors Toho Holdings and Hisamitsu Pharmaceutical, has taken shareholdings in GNI Group as part of the consideration structure.
The deal hands GNI Group a business with JPY 38.5 billion in revenue for the fiscal year ending March 2026, anchored by Calonal, an acetaminophen analgesic that has been in Japanese clinical use for more than 40 years. Ayumi holds approximately 83% of the domestic acetaminophen market and has an established sales network covering orthopaedic and rheumatology practices across Japan. GNI has confirmed that the Ayumi name and all existing product brands will be preserved.
Strategic rationale
GNI Group's president and chief executive Ying Luo described the closing as "an extremely important milestone in further strengthening our global business foundation," framing it as the start of what the company is calling its "Second Founding Phase." The acquisition fills what management had long identified as the missing element in GNI's multi-region model: a domestic Japanese revenue base to sit alongside its operations in the United States, China and Australia.
The company's stated priorities for the combined business are threefold. First, it intends to use Ayumi's existing sales infrastructure to accelerate the introduction of GNI's own pipeline products and international assets into the Japanese market. Second, the stable cash generation from Ayumi's established brands is expected to help fund GNI's broader drug-discovery and development activities, which include its Targeted Protein Degradation platform and lead candidate F351, in development for hepatitis B-related liver fibrosis. Third, a more evenly spread regional revenue base is presented as a hedge against geopolitical concentration risk, a consideration that has grown more prominent for Japan-headquartered companies with significant China exposure.
Market context
The acquisition sits within a broader trend of mid-sized Asian biopharma companies using M&A to secure commercial infrastructure in their home markets before pursuing global expansion. For GNI, which has built out discovery and clinical capabilities ahead of large-scale commercial revenues, absorbing an asset with dominant market share in a stable therapeutic category provides a near-term earnings floor against which more speculative pipeline spending can be funded.
The orthopedic and rheumatology channel that Ayumi has cultivated is also strategically relevant: it is a natural fit for GNI's stated pipeline interests in inflammatory and fibrotic diseases, potentially reducing the cost of launching follow-on products in Japan. Whether GNI can translate Ayumi's volume-driven, off-patent business into a platform for higher-margin specialty launches will be the key operational question for investors over the next two to three years. The inclusion of Hisamitsu Pharmaceutical as a new shareholder is notable; the transdermal drug-delivery specialist could signal future co-development or co-promotion possibilities, though GNI made no such commitment in the announcement.